Genferon Light 125,000 IU suppositories, 10 pcs.

Composition of the drug Genferon Light

Vaginal and rectal suppositorieswhite or white with a yellowish tint, cylindrical in shape with a pointed end, uniform in longitudinal section; The presence of an air core or a funnel-shaped depression on the cut is allowed.

Excipients: “hard fat”, dextran 60,000, macrogol 1500, Polysorbate 80, emulsifier T2, sodium hydrogen citrate, citric acid, purified water.

5 pcs. – blister packs (2) – cardboard packs.

Vaginal and rectal suppositorieswhite or off-white, cylindrical with a pointed end, uniform in longitudinal section; The presence of an air core or a funnel-shaped depression on the cut is allowed.

Excipients: “hard fat”, dextran 60,000, macrogol 1500, Polysorbate 80, emulsifier T2, sodium citrate, citric acid, purified water.

5 pcs. – 2 blister packs – cardboard packs.

Indications

For intranasal use: treatment and prevention of influenza, acute respiratory viral infections, and other acute respiratory viral infections in adults and children 29 days and older (in the appropriate dosage form).

For rectal use: as a component of combination therapy for the treatment and prevention of acute respiratory viral infections and other bacterial and viral infections in children 3 years of age and older (in the appropriate dosage form).

For vaginal use: treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including Pregnant women, while receiving specific therapy prescribed and monitored by a physician.

Pharmacokinetics

Intranasal administration of this combination creates a high concentration of interferon at the site of infection, resulting in a pronounced local antiviral and immunostimulatory effect. Systemic absorption is negligible; with intranasal administration, small amounts of human recombinant interferon alpha-2b are detected in lung tissue and blood. In the body, biotransformation occurs primarily in the kidneys, with a half-life of 5.1 hours. A small amount of this agent entering the systemic circulation exerts a systemic immunomodulatory effect.

Retal administration has high bioavailability (over 80%) of interferon, resulting in both local and pronounced systemic immunomodulatory effects. When administered intravaginally, high concentrations at the site of infection and adherence to mucosal cells result in a pronounced local antiviral, antiproliferative, and antibacterial effect. However, the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. C_max of interferon in serum is reached 5 hours after administration. The primary route of elimination is renal catabolism. T_1/2 is 12 hours.

Pharmacological action of Genferon Light

Combination medicinal product.

Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative, and antibacterial effects. The antiviral effect is mediated by the activation of several intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T-killers, NK cells (natural killers), increased differentiation of B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood of recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin is restored.